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A B S T R A C T
Background: In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup.
Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research.
Methods: To evaluate the impact of ATRX loss of function (LoF) in neuroblastoma, we utilized CRISPR-Cas9
gene editing to generate neuroblastoma cell lines isogenic for ATRX. We used these and other models to iden-
tify therapeutically exploitable synthetic lethal vulnerabilities associated with ATRX LoF.
Findings: In isogenic cell lines, we found that ATRX inactivation results in increased DNA damage, homologous
recombination repair (HRR) defects and impaired replication fork processivity. In keeping with this, high-
throughput compound screening showed selective sensitivity in ATRX mutant cells to multiple PARP inhibi-
tors and the ATM inhibitor KU60019. ATRX mutant cells also showed selective sensitivity to the DNA damag-
ing agents, sapacitabine and irinotecan. HRR deficiency was also seen in the ATRX deleted CHLA-90 cell line,
and significant sensitivity demonstrated to olaparib/irinotecan combination therapy in all ATRX LoF models.
In-vivo sensitivity to olaparib/irinotecan was seen in ATRX mutant but not wild-type xenografts. Finally, sus-
tained responses to olaparib/irinotecan therapy were seen in an ATRX deleted neuroblastoma patient derived
xenograft.
Interpretation: ATRX LoF results in specific DNA damage repair defects that can be therapeutically exploited.
In ATRX LoF models, preclinical sensitivity is demonstrated to olaparib and irinotecan, a combination that can
be rapidly translated into the clinic.
Funding: This work was supported by Christopher’s Smile, Neuroblastoma UK, Cancer Research UK, and the
Royal Marsden Hospital NIHR BRC.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Neuroblastoma, a tumour of the peripheral sympathetic nervous
system is a common, poor outcome tumour of childhood. Half of
patients have clinical high-risk disease at the time of diagnosis,
defined as age greater than 18 months, the presence of distant
metastases and/or amplification of the MYCN oncogene [1]. Despite
intensification of conventional therapies in recent years approxi-
mately half of all children with high-risk neuroblastoma still die with
relapsed/refractory disease [2-4].
Recent studies have found that the majority of poor outcome neu-
roblastoma can be subdivided into three mutually exclusive molecu-
lar subgroups defined by: MYCN amplification (37%), telomerase
reverse transcriptase (TERT) rearrangements (23%) and alpha thalas-
saemia mental retardation X-linked (ATRX) mutations or deletions
(11%) [5,6]. With putative roles in the genesis of biologically
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aggressive disease, these genomic alterations represent attractive
therapeutic targets for high-risk neuroblastoma. In particular, the
ATRX subgroup of neuroblastoma patients has a distinct clinical phe-
notype, with an older age at diagnosis, conventional therapy resis-
tance and a chronic but progressive disease course [7], reinforcing
the notion that alterations in ATRX function underlie the unique
behaviour of these tumours. In support of this, ATRX is the third most
commonly mutated gene across all paediatric malignancies, and
recurrently mutated in poor outcome tumours such as high-grade
glioma and osteosarcoma [8]. Taken together these data indicate that
LoF alterations in ATRX are a likely driver of paediatric cancer biology,
emphasizing the urgent need to develop effective therapeutic strate-
gies for ATRXmutated cancers.
Numerous functions of ATRX could underlie the prominent role of
this gene in cellular biology of these cancers. ATRX plays an impor-
tant role in transcriptional regulation by extensive and not yet
completely understood mechanisms. ATRX is enriched at the silenced
allele of imprinted regions. It is also known to regulate gene tran-
scription via binding to the H3K9me3 mark and also via binding to
and the resolution of G-quadruplex structures [9-11]. ATRX also
orchestrates histone 3.3 deposition within telomeres, and pericentric
DNA, thus maintaining genomic stability in these repetitive regions
[12,13]. Concordant with this, ATRX LoF is the strongest predisposing
factor associated with the development of the recombination medi-
ated telomere synthesis mechanism: alternative lengthening of telo-
meres (ALT) [14].
ATRX has also been implicated in the regulation of DNA damage
repair (DDR) both by non-homologous end joining (NHEJ) and
homologous recombination repair (HRR). DDR reporter plasmid
assays have shown that ATRX knockdown by shRNA in murine glial
cells results in impairment of NHEJ but not HRR [15]. However, in
cancer cell line models siRNA down-regulation of ATRX has been
shown to result in impairment of RAD51 localization to BRCA1, a key
trigger for HRR signalling [16].
In summary the ATRX gene has multiple functions that may
underlie the ability of LoF alterations to influence both disease patho-
genesis and the response to therapeutic agents.
Specifically in neuroblastoma, the commonest genetic alterations
seen are either large multi-exon deletions encompassing the ADD
domain or mutations clustering around the Helicase C-terminal
region [7,17]. As in other cancers, both of these alterations are
thought to result in disruption of normal ATRX function, however
recently it has been shown that ATRX deletions also result in the for-
mation of a truncated in frame fusion protein which redistributes to
promoters of active genes [18].
Here we generated isogenic models of ATRX mutant neuroblas-
toma for mechanistic interrogation, then took an unbiased approach
using high throughput compound screening, in order to identify
which of these potential mechanisms are therapeutically exploitable.
We then validated findings in neuroblastoma models with ATRX dele-
tions/in frame fusions, with the ultimate aim of identifying rapidly
translatable novel therapeutic strategies for this poor outcome group
of patients.
2. Materials and methods
2.1. Cell lines
The SKNSH cell line was obtained from ATCC and cultured in Dul-
becco’s Modified Eagle Medium, supplemented with 10% foetal
bovine serum (Thermo Fisher). The CHLA-90 cell line was obtained
from the Children’s Oncology Group Cell Line Repository and cultured
in Iscove’s Modified Dulbecco’s Medium supplemented with 20% foe-
tal bovine serum (Thermo Fisher). Both cell lines were verified by
short tandem repeat DNA profiling and confirmed to be mycoplasma
free using the LookOut mycoplasma PCR detection kit.
2.2. CRISPR Cas9 gene editing
NickaseNinja CRISPR Cas9 constructs (DNA 2.0) were designed
using the company’s gRNA design tool and checked to ensure target
specificity, using the Basic Local Alignment Search Tool (BLAST -
https://blast.ncbi.nlm.nih.gov). The TP53 gRNA was designed to tar-
get exon 3 and the ATRX gRNA to target the helicase C terminal
domain. Twenty-four hours following transfection with the ATRX
CRISPR Cas9 plasmid or the TP53 CRISPR Cas9 plasmid, single cells
expressing RFP-Paprika or GFP (depending on the construct) were
FACS sorted into 96 well plates and then expanded to create stable
TP53 and ATRX knockout cell lines.
2.3. Generation of AMC-772 PDX model
The AMC-772 organoid was established as previously described
[19] and then used to establish a xenograft model. Ethical approval
was obtained under project number AVD3990020173068, study pro-
tocol PMC.63.3068.1801. 4.3 £ 106 AMC772T cells were xenografted
into both flanks of four NMRI nu-/nu- mice at 68 weeks of age.
tumour size was monitored twice a week by calliper measurements
and determined using the formula (p/6)d3. Once the tumour reached
1500 mm3 in size, tumors were passaged to 3 NMRI nu-/nu- mice at
68 weeks of age. Once the tumour reached 1500 mm3 in size,
tumors were cut in pieces and cryopreserved in 10% DMSO for xeno-
transplantation in recipient mice.
2.4. Animal experiments
Mice were subcutaneously injected unilaterally with 1 £ 106 cells
to obtain Passage 0 (P0) xenografts. To improve the latency, xeno-
grafts of both p53(2) and E6 cells were dissociated into single cells
and re-injected into NSG mice twice. P2 xenografts were used for the
pre-clinical trial. AMC-772 P2 xenografts were supplied frozen from
The Princes Maxima centre and passaged once. Calipers were used to
measure tumour diameter on two axes, 23 times per week. 46
Research in context
Evidence before this study
ATRX has been shown to have differing roles in the regula-
tion of DNA damage repair in different cell line and murine
models, hence it has been suggested that DNA damage
response inhibitors may have a role in selectively targeting
some ATRX mutant cancers. ATRX mutations are enriched in
poor outcome paediatric tumours, and specifically in neuro-
blastoma are associated with a chronic refractory phenotype
and poor survival. Novel therapies are urgently needed for this
group of patients.
Added value of this study
We show that in neuroblastoma models, ATRX loss of
function results in impairment of DNA damage repair by
homologous recombination and impaired replication fork
processivity. In keeping with this, using a screen of over 400
compounds, we identify PARP inhibitors as the most signifi-
cant hit showing selective sensitivity in ATRX mutant cells.
We then demonstrate that the combination of the PARP
inhibitor olaparib with the DNA damaging agent irinotecan is
effective in pre-clinical neuroblastoma models with genetic
alterations in ATRX.
Implications of all the available evidence
Our pre-clinical data supports the development of clinical
trials of PARP inhibitor combination therapy for children with
neuroblastoma associated with genetic alterations in ATRX.
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animals were enroled onto each treatment arm once the tumour size
reached 510 mm. Studies were terminated when the mean diame-
ter of the tumour reached 15 mm. Doses administered were: olaparib
50 mg/kg twice daily for 2 weeks, irinotecan 1.35 mg/kg daily for 2
weeks, temozolomide 8 mg/kg for 1 week. All experimental protocols
were approved and monitored by The Institute of Cancer Research
Animal Welfare and Ethical Review Body (PPL 70/7945, later PPL
P91E52C32), in compliance with the UK Home Office Animals (Scien-
tific Procedures) Act 1986. Antibodies used for immunohistochemis-
try were: ATRX (Santa Cruz, sc-55,584), Ki67 (BD biosciences,
556,003).
2.5. Immunofluorescence and immunoblotting
Immunoblotting for ATRX and p53, and Immunofluorescence for
phosphorylated histone H2AX(ser139) (gH2AX) foci was performed in
untreated cells. Immunofluorescence for RAD51/BRCA1 and gH2AX/
DNAPK(ser2056) was performed at eight hours and 30 minutes respec-
tively post irradiation (10 gray), or 24 h following the addition of
5 mM irinotecan. Antibodies used for immunofluorescence and
immunoblotting studies were: ATRX (Sigma - HPA001906), GAPDH
(Cell signalling  2118), phospho-H2AX(ser139) (Cell signalling 
76,310), PARP (Cell signalling  9532), HRP conjugated p53 (R&D sys-
tems  HAF1355), BRCA1 (Santa Cruz  sc6954), RAD51 (Abcam 
ab63801), DNAPK(ser2056) (Cell signalling  12,311).
2.6. DNA fibre assay
7.5 £ 106 cells were seeded and left to attach for at least four
hours before labelling with a 25mM CldU pulse for 20 min, then
either left untreated or exposed to 4mM HU +/- 50 mMmirin for five
hours. Cells were trypsinised and re-suspended in cold PBS to a final
volume of 4 £ 105 cells/ml. 2mL of cells were mixed with 7mL of
spreading buffer (200 mM TrisHCl, pH 7.4, 50 mM EDTA, and 0.5%
SDS) on a glass slide, incubated for two minutes, then tilted 1545°
to allow the DNA spreads to run down the slide, then air dried, fixed
in 3:1 methanol:acetic acid, and refrigerated overnight.
DNA fibres were then denatured in 2.5 M HCl for one hour,
washed with PBS, and blocked with 1% BSA in PBS-T (PBS and 0.1%
Tween 20) for one hour. CldU DNA tracts were labelled for one hour
with 1:1000 rat a-BrdU (Biorad, UK) rinsed with PBS and the second-
ary antibody was applied (a-rat AlexaFluor 555 at 1:500). After fur-
ther PBS washes, coverslips were applied using Vectashield (Vector
Laboratories) and slides stored at 20 °C. The DNA fibres were visual-
ised using an Olympus FV1000 confocal microscope with a PLAPON
60x oil objective lens and a laser of 542 nm wavelength. DNA fibre
lengths were measured in ImageJ (Bethesda, MD, USA). Indicated
numbers of labelled DNA fibres from three independent experiments
per condition were imaged.
2.7. High throughput compound screening
Compounds were obtained from multiple sources including col-
lections from MicroSource Discovery Systems, Inc (US Drug Collec-
tion), ENZO Life Sciences (FDA approved Library, BML-2841),
Prestwick Chemical (Prestwick Chemical Library) and a collection of
commercially available signal transduction inhibitors. Library 1 con-
tains 390 compounds tested at 4 dose levels with a maximum dose of
0.5 mM. Library 2 contains 80 compounds tested at 8 dose levels with
a maximum dose of 1 mM, (Table S1 and S2). Wells containing 0.2%
DMSO, were used as a control for viability, and vials containing 2 mg/
ml puromycin were used as a control for cell death.
Both screens contained 2 independent replicates of the SKNSH cell
line and the isogenic cell lines generated from SKNSH by CRISPR Cas9
deletion of TP53 and ATRX named: p53(2) (TP53 mutant), A3, E1 and
E6 (generated from p53(2), mutant for both TP53 and ATRX). 500 cells
per well were plated in opaque 384 well plates and after 24 h of incu-
bation compounds were then added in triplicate for each dose level.
After 5 days incubation, cell viability assessed by Cell Titre Glo. Pear-
son’s correlation between normalised values for each replicate was
between 0.94 and 1. For each compound AUC was calculated using
the drc R-package as a read out for drug sensitivity.
Linear mixed effects models were used to test for differences in
AUC for each compound dependant on ATRX gene status. Fixed effects
(ATRX gene status) and random effects (replicate screen for each cell
line) were coded as factors and the drc R-package was used to fit
models. Compounds where the fixed effect (ATRX gene status) was
nominally significant (uncorrected p-value  0.05) were selected. In
addition, we focused on those compounds where the magnitude of
the difference between the wild type and ATRX mutant group was
greatest, specifically focusing on those compounds where the differ-
ence in AUC between the wild type and ATRX mutant groups were
greater than 0.1 (with 1.0 being the maximum AUC corresponding to
no inhibition of growth).
2.8. Sequencing
WGS was done at the Genomic and Proteomics sequencing core
facility at the German Cancer Research centre (DKFZ), Heidelberg,
Germany. DNA was isolated using the Invitrogen PureLink DNA
mini kit according to manufacturer’s instructions. Library preparation
was done using the Truseq DNA Nano kit (Illumina) and libraries
were size selected using SPRI beads (Beckman Coulter Genomics).
Samples were sequenced on the Illumina Hiseq X Ten platform using
150 bp paired end sequencing with 60 X coverage. Samples were
aligned by the One Touch Pipeline (OTP) service at the German Can-
cer Research centre (DKFZ). WGS data was aligned to the 1KGRef_-
PhiX reference genome using BWA-MEM version 0.7.15 (option -T 0).
Sambamba version 0.6.5 was used for merging and duplication mark-
ing. Samtools version 0.1.19 was used to filter and sort the bam files.
This in-house workflow was recently described in detail by Jabs. et al.
[20]. NGS Panel sequencing was analysed as previously reported [21].
2.9. SF50 experiments
SF50 experiments were performed in 96 well plate format. The
number of cells used for each SF50 experiment was determined in a
prior experiment to evaluate the number of cells necessary to reach
7090% confluency by the desired time-point. Cells were seeded into
96-well plates and the following day compound was added to wells
in triplicate, across a concentration gradient including one three well
replicate of DMSO-only controls. At the relevant time point cell via-
bility was assessed by Cell titre Glo assay. The SF50 was calculated as
the drug concentration that inhibits viability/cell growth by 50% com-
pared with controls, according to non-linear regression analysis,
using Graphpad Prism. Olaparib, rucaparib, talazoparib, KU60019 iri-
notecan and temozolomide were purchased from SelleckChem, Sapa-
citabine was purchased from AdooQ Bioscience.
2.10. PARP siRNA
Two different ON-TARGETplus siRNAs targeting PARP1 (#J-
006,656060002 and #J-006,656070002) and a non-targeting
control siRNA (#D-001,8100105) were purchased from Dharma-
con. Cells were transfected with Dharmacon 1 transfection agent as
per the manufacturers instructions. PARP1 downregulation was
assessed by western blotting and cell viability by Cell titre Glo assay.
Survival in cells following PARP1 knockdown was normalized to the
non-targeting control siRNA.
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2.11. Pharmacodynamic assays
The HT PARP in-vivo pharmacodynamic assay kit (Trevigen) was
utilized to quantify PAR levels as per manufacturers instructions. For
the CHLA90 cell line the assay was performed 24 h after treatment
with vehicle versus 1 mM olaparib. For in-vivo studies, PAR levels
were quantified one hour after administration of either 50 mg/kg ola-
parib or vehicle.
2.12. Statistical analyses and data
All results are expressed as mean +/- standard deviation unless
otherwise indicated. Statistical analysis of compound screen data
using linear mixed effects models was done using the R package as
indicated above. All other statistical analysis was done using graph-
pad prism version 7.
2.13. Role of funding source
Financial support for this work was provided by the charities
Christopher’s Smile, Neuroblastoma UK, Cancer Research UK, and the
Royal Marsden Hospital NIHR BRC. None of these organizations had
any role in the study design, data collection, data analyses, interpre-
tation, or writing of report.
3. Results
3.1. ATRX CRISPR Cas9 knock-out in neuroblastoma cell lines results in
HRR deficiency and impairment of replication fork processivity
In neuroblastoma, ATRX alterations and ALT are mutually exclu-
sive with MYCN amplification [22]. In order to identify biologically
relevant models of neuroblastoma we evaluated a panel of 7 MYCN
non-amplified neuroblastoma cell lines for ATRX protein expression
and telomerase activity (Fig. S1 a-b). The SKNSH cell line was
selected for ATRX gene editing as it expresses high levels of ATRX,
and does not display the ALT phenotype. The only other cell line iden-
tified fulfilling these criteria was NBL-S, however this cell line is
known to express high levels of MYCN [23].
We surmised that generation of stable ATRX-deleted cells would
require prior p53 inactivation, given that ALT neuroblastoma cell
lines frequently show p53 pathway aberrations [24], CRISPR Cas9
gene-editing activates p53-mediated DNA damage repair in differen-
tiated cells [25], and that ATRX loss results in p53-driven apoptotic
cell-death in neural progenitors [26].. Indeed, ATRX knockout via
CRISPR Cas9 was lethal in TP53 wild type SKNSH cells (Fig. S1 c-e),
and as expected [25,26] drove high-levels of apoptosis in TP53 wild
type cells (Fig. S1f). However, with prior deletion of TP53, we gener-
ated three stable cell lines by CRISPR Cas9 ATRX gene editing (named
as A3, E1 and E6) that were devoid of ATRX expression (Fig. 1a).
Whole genome sequencing (WGS) confirmed presence of the small
indels in the targeted region of TP53, and differing indels in the tar-
geted region of ATRX in the A3, E1 and E6 clones (Table S1, Fig. S1h).
In untreated ATRX mutant cell lines we observed an increase in
the number of gH2AX foci (Fig. 1b-c), suggesting an increase in
stalled and collapsed replication forks. Given that ATRX plays a key
role in the regulation of DNA damage repair pathways, we asked
whether the increase in gH2AX could represent a failure to effec-
tively repair DNA lesions due to a defect in activation of canonical
double stranded DNA repair mechanisms: NHEJ and HRR. Induction
of DNA damage via ionizing irradiation resulted in auto-phosphoryla-
tion of DNA dependant protein kinase (DNA-PK(ser2056)) and localiza-
tion to sites of DNA damage in both ATRX wild type and mutant cells
(Fig. 1d-e), this suggests that ATRX mutant cells are still proficient in
the initiation of DNA repair by NHEJ [27]. Conversely, ATRX mutant
cells exhibited a clear loss of RAD51 and BRCA1 co-localization, an
indicator of defective homologous recombination (Fig. 1f-g). In view
of these findings, we assessed WGS data for off-target mutations in
genes with known roles in HRR that could explain the observed HRR
deficiency in the CRISPR Cas9 edited isogenic cell lines (Table S1).
This confirmed no off-target exonic variants or indels in any of the
CRISPR Cas9 generated cell lines, suggesting the ATRX LoF mutations
could be the cause of the RAD51 defect. WGS data were also used to
generate homologous recombination deficiency (HRD) scores [28].
There was no significant increase in the overall score in ATRXmutant
cell lines, but one of the contributing parameters: the number of telo-
meric allelic imbalance events was increased in the ATRX mutant
lines (Table S1), in keeping with the known role of ATRX in telomere
maintenance [29] and also indicative of DNA repair deficiencies [30].
The ability to faithfully replicate DNA is another key hallmark of
genomic integrity and both p53 and ATRX are reported to protect
stalled replication forks [16,31]. We evaluated mean DNA fibre
length, as a marker of replication fork processivity. As expected TP53
knockout resulted in a significantly lower mean DNA fibre length and
this was further enhanced by mutation of ATRX (Fig. 2a-d). In the
presence of hydroxyurea induced replication stress, all three cell lines
exhibited shortened fibre lengths compared to untreated cells sug-
gesting increased fork stalling as would be expected. However the
degree of shortening was far greater in ATRX mutant cells compared
to the other cell lines. This suggests that ATRX either reduces stalling
or has a protective role at stalled forks. In keeping with the ability of
ATRX to bind to and inhibit MRE11, an exonuclease that degrades
stalled forks following DNA damage [16] the MRE11 inhibitor mirin
was able to reverse the effects on fibre lengths only in the ATRX
mutant cells (Fig. 2e-g). This strongly suggests that ATRX mediates
MRE11-dependant degradation at stalled replication forks in the con-
text of neuroblastoma.
Taken together, these data indicate that ATRX plays an important
role in maintenance of DNA / genome integrity in neuroblastoma
cells, through regulation of DNA repair mechanisms and maintenance
of replication fork stability.
3.2. High-throughput small molecule inhibitor screening identifies
specific ATRX dependant DNA damage repair pathway vulnerabilities
and PARP inhibitor sensitivity
To identify therapeutic sensitivities relating to ATRX deficiency,
we performed high-throughput small molecule inhibitor sensitivity
screens using compound libraries containing inhibitors of DNA repair,
in addition to a broad range of conventional chemotherapy agents
and small molecules that target wide-ranging, cancer relevant path-
ways. The panel of isogenic cell lines varying in ATRX and TP53 status
was screened with two clinical compound libraries. A broad screen
containing 390 compounds tested at 4 dose levels (screen 1) and a
narrower but more sensitive screen containing 80 compounds tested
at 8 concentrations (screen 2) (Table S2).
Of the 390 distinct compounds tested in screen 1, three com-
pounds met the criteria for ATRX synthetic lethality. This was arbi-
trarily defined as both a statistically significant difference in AUCs
between the wild type and ATRX mutant groups, and a difference in
mean AUCs between the wild type and ATRX mutant groups of
greater than 0.1 (Fig. 3a). The strongest hit identified was the clinical
poly-(ADP-Ribose) polymerase (PARP) inhibitor talazoparib [32]. No
clear sensitivity patterns were identified for other modulators of
DNA damage repair (Fig. S2a). The other compounds identified with
selective sensitivity were the heat shock protein 90 (HSP 90) inhibi-
tor: 17-AAG [33], and the amino-peptidase inhibitor tosedosat [34].
Fourteen compounds met the criteria for selective resistance in the
ATRX mutants, including three different histone deacetylase (HDAC)
inhibitors and two different aurora kinase inhibitors, where a clear
trend towards relative resistance was identified for multiple com-
pounds from both classes of agent (Fig. 3a, Fig. S2b).
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In screen 2, nine distinct compounds met the criteria for selec-
tivity. In all cases the significant differences in AUC represented
greater sensitivity in the ATRX mutant group relative to the wild-
type group (Fig. 3b). Of the nine distinct compounds identified as
selective against the ATRX mutants, five of these implicated vul-
nerabilities in DNA damage repair mechanisms (Fig. 3b, Fig S3a).
Selective sensitivity to all three clinical PARP inhibitors contained
in the screen was identified (talazoparib, rucaparib and olaparib)
and independently verified (Fig 3b, Fig S3 b-d, g). The ATRX
mutants also showed selective sensitivity to the toolbox ataxia
telangiectasia mutated (ATM) inhibitor KU60019 and to sapacita-
bine, an inducer of DNA double strand breaks known to be effec-
tive in models of HR deficient cancer (Fig. 3b, Fig S3 e-g) [35].
Aside from inhibitors of the DNA damage response, additional
Fig. 1. Generation of stable ATRX CRISPR Cas9 knock-out neuroblastoma cell lines results in increased DNA damage and HRR deficiency. (a) Western blot showing ATRX and p53
expression in the isogenic panel of cell lines generated by CRISPR Cas9 gene editing of SKNSH (b) Proportion of untreated cells with >5 gH2AX foci (error bars represent SD from 2
independent experiments, minimum 140 cells, p<0.0001 by one-way Anova). (c) Representative images showing gH2AX foci in untreated cells. (d) Quantification of the overlap
coefficient of gH2AX and pDNAPK foci by immunofluorescence, 30 min post 10 Gy irradiation (IR) versus control (cont), in p53(2) and E6 cell lines (e) Representative images from
pDNAPK (red) and gH2AX (green) co-localisation experiment. (f) Quantification of the overlap coefficient of BRCA1 and RAD51 foci by immunofluorescence, 8 hours post 10 Gy IR
versus cont, in p53(2) and E6 cell lines. (g) Representative images from BRCA1 (red) and RAD51 (green) co-localisation experiment. For co-localisation experiments a minimum of
100 cells from 2 experiments were analysed by the ZEN software co-localisation analysis tool. Error bars represent SEM.
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compounds identified by the screen with a high degree of prefer-
ential sensitivity in the ATRX mutants were the multi-tyrosine
kinase inhibitor sunitinib [36] and, in keeping with screen 1, the
HSP 90 inhibitor: 17-AAG [33].
Taken together, the combined findings from both screens indi-
cate specific vulnerabilities in DNA damage repair in the ATRX
mutants, with broad class specific sensitivity identified to PARP
inhibitors. In keeping with this, genetic knockdown of PARP-1 also
reduced cell viability in ATRX mutant cells in comparison with the
parent cell line (Fig. 3c-d). We therefore focused on further pre-
clinical evaluation of the PARP inhibitor olaparib as a therapeutic
strategy for ATRX mutant neuroblastoma. This agent is already
clinically approved in adult use and is in clinical trials for children
so there is greater potential for rapid translation into the clinic for
this indication.
3.3. PARP inhibition increases sensitivity to irinotecan in models of ATRX
mutant neuroblastoma
In order to maximize the potential therapeutic benefit of PARP
inhibition, we then evaluated compound screen data from the iso-
genic panel to identify potential candidate chemotherapy agents for
combinatorial studies. Evaluation of compound screen data for sensi-
tivity to chemotherapy agents commonly used at the time of neuro-
blastoma relapse showed no differences between the groups in
sensitivity to temozolomide, topotecan or cyclophosphamide
(Fig. S4a-c) but revealed that although loss of TP53 results in irinote-
can resistance, loss of ATRX re-sensitises cells to irinotecan (Fig. 4a).
Preferential sensitivity to irinotecan in the ATRX mutant cells was
subsequently verified, and combination therapy with olaparib evalu-
ated (Fig. 4b). Although the addition of olaparib significantly
Fig. 2. ATRX facilitates replication fork processivity and fork protection in neuroblastoma cells. (a) SKNSH, p53(2) and E6 cells were pulsed with CldU and subsequently exposed to
hydroxyurea (HU) and mirin for five hours as indicated in the schematic. (b) Representative fibre images (c) Distribution of DNA fibre length for untreated cells together with (d)
mean fibre length. p53 knockout results in significantly reduced mean DNA fibre length which is further reduced with loss of ATRX. Data pooled from three independent repeats to
show the distribution of DNA fibre length with the median indicated by the black line. Total fibres counted are as follows: SKNSH (n = 241), p53- (n = 165), ATRX- (n = 350). The data
for mean fibre length are presented as the mean +/- SEM for three independent repeats. Response of (e) SKNSH, (f) p53(2) and (g) E6 cells to HU treatment alone or with mirin. The
data for mean fibre length are presented as the mean +/- SEM for three independent repeats. Significance determined by student’s unpaired t-test where ***p <0.001, **p <0.01,
*p <0.05.
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enhanced irinotecan sensitivity regardless of ATRX status, the cumu-
lative sensitivity to the combination of irinotecan and olaparib was
significantly greater in the ATRX mutants (Fig. 4b). Irinotecan stabil-
izes single strand breaks induced by topoisomerase 1 and is known
to induce double strand DNA breaks through collapse of replication
forks (37, 38). In keeping with impairment of HRR signalling at sites
of irinotecan induced double stranded DNA damage, ATRX mutant
cells were unable to co-localise RAD51 to BRCA1 following irinotecan
therapy (Fig. 4c).
The failure of HRR signalling via the RAD51-BRCA1 co-localisation
in response to irinotecan was also demonstrated in the ATRX deleted/
in frame fusion cell line CHLA-90 (Fig. 4d-e). Finally, although CHLA-
90 is relatively resistant to single agent olaparib the addition of ola-
parib at a low dose was sufficient to inhibit downstream PARP and
significantly sensitized the CHLA-90 cell line to irinotecan (Fig. 4f
and Fig. S4 d-f).
Taken together, this indicates that in neuroblastoma models, loss
of normal ATRX function is associated with HRR deficiency and a lack
of protection of stalled replication forks, thus sensitivity to PARP inhi-
bition, particularly when combined with DNA damaging agents.
3.4. Olaparib and irinotecan therapy causes tumour regression in-vivo
in ATRX mutant but not ATRX wild type xenografts
For in-vivo studies subcutaneous xenografts were established in
NOD scid gamma (NSG) mice using the p53(2) and E6 cell lines.
The median time from injection to tumour onset was significantly
longer in the E6 xenografts in comparison with p53(2) xenografts
(Fig. S5 a-b). Loss of ATRX expression seen in the E6 xenografts by
immunohistochemistry (IHC) but Ki67 staining was seen in both
xenografts (Fig. 5a). As published in preclinical Ewing sarcoma
studies [39], pharmacodynamic inhibition of PARP activity in both
Fig. 3. Therapeutic screening identifies specific ATRX dependant DNA damage repair vulnerabilities and PARP inhibitor sensitivity. (a) Volcano plots showing the difference in mean
AUC and the negative log10 p-value of the difference in the AUC between the ATRX mutant and wild type groups for the 390 compounds tested in screen 1. Compounds fulfilling the
criteria for selective sensitivity in the ATRX mutants are highlighted in the top left quadrant. Compounds fulfilling the criteria for selective resistance in the ATRX mutants are
highlighted in the top right quadrant. (b) Volcano plots showing the difference in mean AUC and the negative log10 p-value of the difference in the AUC between the ATRX mutant
and wild type groups for the 80 compounds tested in screen 2 (c) Cell viability as measured by CellTiter-glo following genetic knockdown of PARP 1 with two different siRNAs, (nor-
malized to control siRNA) in isogenic cell lines. (d) Western blot showing PARP 1 levels in same experiment as (c).
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p53(2) and E6 xenografts was confirmed at a dose of 50 mg/kg ola-
parib (Fig. 5b). On day 14 of olaparib/irinotecan combination ther-
apy, tumour regression was observed in E6 xenografts but there
was progressive disease in all treatment arms in the p53(2) xeno-
grafts (Fig. 5c-e, Fig. S5c-d). This translated into a small increase
in survival in the E6 xenograft model following only 1 cycle of ola-
parib/irinotecan therapy (Fig. 5f-g).
Although all cell lines were highly resistant to temozolomide in-
vitro (Fig. S6a), some sensitization to temozolomide was
demonstrated with the addition of olaparib, particularly in the E6 cell
line (Fig. S6b). This, in combination with the fact that temozolomide
is also used as standard backbone chemotherapy in relapsed neuro-
blastoma trials, prompted us to evaluate the combination of temozo-
lomide and olaparib in-vivo. In contrast to single agent irinotecan,
single agent temozolomide caused tumour regression in E6 xeno-
grafts. However, although the addition of olaparib to temozolomide
did slow tumour growth, this did not translate to increased survival
(Fig. S6).
Fig. 4. PARP inhibition increases sensitivity to irinotecan in ATRX mutant neuroblastoma. (a) AUC scores for irinotecan from the compound screen, subdivided into TP53 and ATRX
status. (b) Summary of SF50 results for irinotecan alone or given in combination with 1 mM olaparib in ATRX wild type/mutant isogenic cell lines from 3 independent experiments.
(c) Quantification of the overlap coefficient of BRCA1 and RAD51 foci by immunofluorescence, 24 h post irinotecan versus vehicle in p53(2) and E6 cell lines. (d) Quantification of
the overlap coefficient of BRCA1 and RAD51 foci by immunofluorescence, 24 h post irinotecan versus vehicle in the CHLA90 cell line, compared with aMYCN amplified cell line. For
(c) and (d), a minimum of 100 cells from 2 experiments were analysed by the ZEN software co-localisation analysis tool. Error bars represent SEM (e) Representative images from
BRCA1 (red) and RAD51 (green) co-localisation experiment from (d). (f) comparison of the SF50 for irinotecan +/- olaparib 1mM in the ATRX deleted cell line CHLA90, by three inde-
pendent experiments, p value by unpaired students t-test.
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Fig. 5. Olaparib and irinotecan therapy causes tumour regression in-vivo in ATRXmutant but not ATRXwild type xenografts. (a) Representative immunohistochemistry for ATRX and
Ki67 (b) PAR activity by HT PARP in-vivo pharmacodynamic assay kit in p53(2) and E6 xenografts after treatment with vehicle versus 50 mg/kg olaparib for 1 h. PAR is quantified as a
read out of relative light units (RLU) (c) Treatment schedule - animals received one 3 week cycle of treatment (d) Waterfall plot showing day 14 responses in individual p53(2) xeno-
grafts (e) Waterfall plot showing day 14 responses in individual E6 xenografts (f) Kaplan-Meier curve of survival following one cycle of therapy in p53(2) xenografts. No significant
difference in survival (g) Kaplan-Meier curve of survival following one cycle of therapy in E6 xenografts. *p<0.001 survival in olaparib/irinotecan versus other arms by unpaired stu-
dents t-test.
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3.5. Olaparib/irinotecan combination therapy induces sustained
remissions in an ATRX deleted patient derived xenograft (PDX)
neuroblastoma model
We established subcutaneous xenografts in NSG mice, using the
AMC-772 neuroblastoma PDX. Western blot confirmed an absence of
full-length ATRX protein expression and the presence of a truncated
protein in AMC-772, that is consistent with an in frame fusion
(Fig. 6a). Using a paediatric solid tumour next generation sequencing
panel (21) an ATRX multi-exon deletion was confirmed in the AMC-
772 PDX. TP53 was wild type. There was mosaic ATRX expression on
IHC, but diffuse Ki67 staining (Fig. 6b). On day 14 of therapy some
response was seen in the irinotecan alone group, which was further
improved by the addition of olaparib (Fig. 6c). Furthermore, sus-
tained responses were seen to just one cycle of olaparib/irinotecan
therapy, which translated to significantly improved survival in the
olaparib/irinotecan group (Fig 6. d-e).
4. Discussion
Despite urgent clinical need, there is currently a dearth of pre-
clinical research focused on the identification of novel therapeutic
strategies for children with ATRX mutant neuroblastoma. This is
partly due to the lack of available models for this subgroup of
patients. Here we address this by utilizing CRISPR Cas9 genetic engi-
neering to generate isogenic models of ATRX mutant neuroblastoma,
followed by unbiased screening and mechanistic studies in order to
identify therapeutic vulnerabilities associated with ATRX LoF.
In this study we identify both reduced replication fork processiv-
ity and protection and impaired HRR signalling as a consequence of
ATRX mutation which is consistent with others findings following
ATRX siRNA in HELA cancer cells lines [16]. In keeping with this, we
demonstrate that ATRXmutant neuroblastoma cells are preferentially
sensitive to PARP inhibitors, which are known to be synthetically
lethal in HRR deficient cancers [40,41]. In contrast, in a murine model
of glioma, following ATRX shRNA, a loss of pDNA-PKcs foci was dem-
onstrated, and consistent with this an impairment of DNA repair by
NHEJ was identified [15]. These relative phenotypic differences may
be accounted for by differences in the model systems used and the
degree of ATRX down-regulation by the different methodologies.
However, as the primary aim of this study was to identify clinically
translatable synthetic lethal approaches, we therefore decided to use
a compound screening approach to further elucidate the most rele-
vant DNA damage repair pathway vulnerabilities in ATRX LoF neuro-
blastoma models.
In addition to PARP inhibitor sensitivity, we also identify preferen-
tial sensitivity to sapacitabine in the ATRXmutated isogenic cell lines.
Sapacitabine is a nucleoside analogue that induces double stranded
DNA breaks, and has also been shown to be effective in other HRR
deficient cancers [35,42]. Therefore further evaluation of this agent
for ATRX mutant/deleted neuroblastoma and other HRR deficient
childhood tumours is also warranted.
Activation of ATM has been reported in other models of ATRX loss
of function and ATRX null cells are thought to rely on ATM associated
pathways for DNA repair [16,43]. We identify preferential sensitivity
to the toolkit ATM inhibitor KU60019 in the ATRX mutants. The clini-
cal ATM inhibitor AZD0156 is currently in phase 1 trials in adults
with advanced solid tumours in combination with either olaparib or
irinotecan [3335,41]. There would therefore also be a strong ratio-
nale for further pre-clinical testing of these AZD0156 combinations
for ATRXmutant neuroblastoma.
The other major result from the compound screen was the identi-
fication of preferential sensitivity to the HSP90 inhibitor 17-AAG in
the ATRX mutants in both screens. HSP90 inhibitors have been
reported to be effective in a broad range of malignancies through
inhibition of interactions with multiple different client proteins
which play major roles in oncogenic signalling [44]. ATM has been
shown to be a client of HSP90, and inhibition of HSP90 with 17AAG
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induces proteosomal degradation of ATM [45,46]. Furthermore,
BRCA1 deficient cells have been shown to be hypersensitive to
17AAG [47]. Taken together with the other findings in the screen, it is
probable that 17AAG sensitivity in ATRX mutant cell lines, is at least
in part a result of the downstream effects on the DNA damage
response pathways.
In addition to identifying compounds that are selective for ATRX
mutant cells, we also identified two classes of compound where there
is relative resistance. HDAC inhibitors selectively kill cancer cells via
inhibition of the many functions of HDAC proteins including chroma-
tin remodelling and the modulation of gene transcription, which are
thought to play a role in cancer development and progression [48].
The mechanism for relative HDAC resistance in the ATRX mutants is
not certain but it may be that the resultant far-reaching epigenetic
changes of ATRX LoF render HDAC mediated mechanisms less impor-
tant for cancer cell survival. The mechanism of resistance to aurora
kinase inhibitors is also unclear, although of note, both aurora kinase
A and B has been shown to phosphorylate HDAC1. Therefore aurora
kinase is implicated in the maintenance of HDAC enzymatic activity
[49]. The relative resistance to aurora kinase inhibition identified by
the screen is also in direct contrast with the preferential pre-clinical
sensitivity of MYCN amplified neuroblastoma to aurora kinase A
inhibitors [50], emphasizing the importance of molecular pre-selec-
tion for trials of novel agents in neuroblastoma patients.
The identification of specific DDR pathway vulnerabilities was the
most significant finding from our screen. We decided to further vali-
date PARP inhibition as a therapeutic strategy for ATRX mutant neu-
roblastoma, specifically olaparib, as a clinically available agent, which
is already available in paediatric clinical trials, albeit for other indica-
tions. To maximise the potential clinical efficacy, rational combina-
tions with standard therapies for relapsed neuroblastoma were
sought. We identified preferential sensitivity to irinotecan in the
ATRX mutants, which is in keeping with findings in an in-vivo model
of ATRX LoF glioblastoma [15]. There is a strong rationale for this
combination in other paediatric cancer models, where strong synergy
between olaparib and irinotecan has been demonstrated [51], which
we now also identify in neuroblastoma models.
Qadeer et al. recently reported that in neuroblastoma models with
multi-exon ATRX deletions, an in frame fusion protein is expressed
which activates RE1 Silencing Transcription Factor (REST), resulting
in EZH2 inhibitor sensitivity [18]. Of note we show HRR deficiency
and olaparib/irinotecan sensitivity in both ATRXmutant and deletion/
in frame fusion neuroblastoma models. Therefore, this approach
offers the opportunity for therapeutic targeting of loss of normal
ATRX function in neuroblastoma regardless of the whether this
results from a multi-exon deletion or frame-shift mutation.
In summary, we identify a distinct phenotype and clear differen-
tial compound sensitivity patterns following ATRX genetic deletion in
a neuroblastoma model. Furthermore, we identify a rapidly translat-
able therapeutic approach for this poor outcome group of patients.
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